Back in August, the FDA issued an Emergency Use Authorization for convalescent plasma for treating those with COVID-19. With more data in hand, the agency has now limited its use to a subset of hospitalized patients.
From vaping to cutting-edge biotechnology, UK health regulators do a far better job than their American counterparts. This was proven yet again when the UK beat the U.S. FDA at approving a coronavirus vaccine produced by Pfizer, an American company.
The false narrative that prescription drugs caused the opioid crisis has been relentlessly undermined by evidence to the contrary, yet it remains. It may have suffered a ding here and there, but it's still mostly intact. But if evidence really matters, Dr. Jeffrey Singer just gave it another ding. Maybe even a dent. From 2019.
FDA Commissioner Stephen Hahn indicated that his agency would be willing to grant emergency authorization to a coronavirus vaccine, even before it completes Phase 3 clinical trials. This is a reckless gamble and could cause an unmitigated public health disaster.
The FDA’s rigorous oversight – rather than a race to satisfy an aggressive agenda – is imperative during this pandemic.
Perhaps someday a ballad will be written about the tragic tale of hydroxychloroquine (HCQ) and its ugly cousin chloroquine (CQ). HCQ, a potential (and controversial) therapy for COVID-19 at one time, is no more. The FDA revoked the emergency authorization of both HCQ and CQ. This was an example of how NOT to develop a drug. A lesson learned -- or not.
As new breeding techniques create new ethical debates over food, we think the ethical toolbox needs updating. Talking about crossing species lines simply isn’t enough. If Darwin had known about gene editing, we think he would have agreed.
Virtually every day there's news about one or more clinical trials in progress or being planned. But most people don't fully understand what the different trials mean. ACSH advisor Dr. Katherine Seley-Radtke gives us a primer that clearly explains the entire process. Timely reading.
COVID-19 has spread across the media much faster than across the world. The uptick is seen in the articles we're bringing forward this week. But rather than concentrate on what to do -- which has already been amply covered -- we're sharing reflections on how we got here. And what we can do differently.
We are holobionts, those who thrive in a saline environment, crafting of at least two species living in close proximity with one another. The other species is our gut microbiome, those microbial communities residing in our bowels and providing us with nutrients and signals. There's no denying their importance. But not as much can be said for probiotics –- the live microorganisms marketed to us with claims to better our health.
We wrote a little over a month ago about the large number of institutions not reporting study results, as required on ClinicalTrials.gov. Now, Stat reports that a federal court has ruled that those reports must be filed, although the timeframe for compliance remains ambiguous.
If you're a government agency like the CDC, the best time to admit to a huge mistake is on Friday afternoon before a three-day weekend. And if you're a government agency like the FDA, there's never a good time to make a boneheaded decision.